MYND Lifesciencs Inc
MYND Life Sciences Inc., a life sciences-based neuro-pharmaceutical drug development company, advances medicines based on neuro-anti-inflammatory substances for depressive disorders through science and clinical trials in Canada and the United States. It focuses on the analysis of psilocin and psilocybin extracts, and analogs. MYND Life Sciences Inc. is based in Port Coquitlam, Canada.
Market Cap & Net Worth: MYND Lifesciencs Inc (MYNDF)
MYND Lifesciencs Inc (PINK:MYNDF) has a market capitalization of $478.17K ($478.17K) as of March 20, 2026. Listed on the PINK stock exchange, this USA-based company holds position #38276 globally and #12458 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying MYND Lifesciencs Inc's stock price $0.01 by its total outstanding shares 47817182 (47.82 Million).
MYND Lifesciencs Inc Market Cap History: 2025 to 2025
MYND Lifesciencs Inc's market capitalization history from 2025 to 2025. Data shows growth from $478.17K to $478.17K (0.00% CAGR).
MYND Lifesciencs Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how MYND Lifesciencs Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of MYNDF by Market Capitalization
Companies near MYND Lifesciencs Inc in the global market cap rankings as of March 20, 2026.
Key companies related to MYND Lifesciencs Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #159 globally with a market cap of $115.97 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $72.67 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #339 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #492 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #159 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $115.97 Billion | $458.05 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $72.67 Billion | $737.45 |
| #339 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #492 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
MYND Lifesciencs Inc Historical Marketcap From 2025 to 2025
Between 2025 and today, MYND Lifesciencs Inc's market cap moved from $478.17K to $ 478.17K, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $478.17K | -- |
End of Day Market Cap According to Different Sources
On Mar 20th, 2026 the market cap of MYND Lifesciencs Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $478.17K USD |
| MoneyControl | $478.17K USD |
| MarketWatch | $478.17K USD |
| marketcap.company | $478.17K USD |
| Reuters | $478.17K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.